Comparación farmacoeconómica (costo – utilidad / beneficio / efectividad) del Rituximab, con el tratamiento convencional para pacientes con Linfoma No Hodgkins
Thesis
The NHL is a malignant cancer that has nationwide low incidence but high costs of care for his handling catalogándose as costly diseaseThe treatment according to treatment phase, histological classification and treatment response to treatment alternatives considered in certain clinical guidelines in this paper we review the chemotherapy (CHOP) and Rituximab + CHOP therapyObjective: To compare the treatment with chemotherapy and Rituximab in cost benefit / utility / effectiveness and impact of both therapies on quality of life and burden of disease from the perspective of the existing regulatory framework and its application in a EPSResults: In the cost-benefit analysis, utility and effectiveness, we found that treatment costs exceed Rituximab chemotherapy, but when comparing the results obtained by DALY and QALY confirmed the results evidenced in literature, which are the variables more sensitive for determining management protocols NHL.Conclusions: Although Rituximab is a good treatment option for non-Hodgkin lymphoma, the costs that are caused by this medicine outweigh the compensation received by these users, it is necessary that public policies relate this analysis to match income to expenses and allow the economic balance of the attention, not allowing for business economics issues are taken that can go wrong alternatives less after the health of users.
